Hyperinsulinemia - Pipeline Review, H1 2018

  • ID: 4576088
  • Report
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Heptares Therapeutics Ltd
  • Rezolute Inc
  • Zealand Pharma AS
  • MORE
Hyperinsulinemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H1 2018, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

Report Highlights:

This latest pipeline guide Hyperinsulinemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Heptares Therapeutics Ltd
  • Rezolute Inc
  • Zealand Pharma AS
  • MORE
Introduction

Report Coverage

Hyperinsulinemia - Overview

Hyperinsulinemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperinsulinemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperinsulinemia - Companies Involved in Therapeutics Development

Crinetics Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

Heptares Therapeutics Ltd

Rezolute Inc

Zealand Pharma AS

Hyperinsulinemia - Drug Profiles

ABGLC-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABI-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-02481 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNB-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperinsulinemia - Dormant Projects

Hyperinsulinemia - Product Development Milestones

Featured News & Press Releases

Apr 09, 2018: Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development

Mar 12, 2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018

Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery

Oct 19, 2016: XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism

Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies

Sep 06, 2016: XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016

Jul 20, 2016: XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism

Jun 16, 2015: XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism (HI)

Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperinsulinemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018

Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Hyperinsulinemia - Pipeline by Heptares Therapeutics Ltd, H1 2018

Hyperinsulinemia - Pipeline by Rezolute Inc, H1 2018

Hyperinsulinemia - Pipeline by Zealand Pharma AS, H1 2018

Hyperinsulinemia - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Hyperinsulinemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Crinetics Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Heptares Therapeutics Ltd
  • Rezolute Inc
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll